Ibogaine Dosing — Clinical Protocols & Safety

Weight-Based Dosing

Ibogaine is dosed by body weight. The standard flood dose range is 10–25 mg/kg. The specific dose within this range is determined by the indication, the patient's medical history, and the form of ibogaine used.

Test Dose Protocol

A test dose (1–3 mg/kg) is administered 30–60 minutes before the full dose to assess cardiac response and individual sensitivity. This is a critical safety measure that should never be skipped.

HCl vs. Total Alkaloid Extract

Ibogaine HCl (the purified compound) and total alkaloid (TA) extract from the Tabernanthe iboga plant have different potencies and pharmacokinetics. Dosing protocols differ between the two forms.

Continuous Monitoring Required

Ibogaine's cardiac effects require continuous monitoring during and after dosing. QTc interval must be assessed before dosing and monitored throughout the session.

Understanding Ibogaine Dosing

Ibogaine dosing is more complex than most pharmaceutical dosing because the therapeutic window (the range between an effective dose and a dangerous dose) is relatively narrow, individual responses vary significantly, and the form of ibogaine used (HCl vs. TA) affects potency. This is why ibogaine dosing is covered in depth in the Tier 2 Clinical Facilitator curriculum — it requires clinical judgment, not just formula application.

Flood dose range: The standard therapeutic flood dose is 10–25 mg/kg of body weight. Lower doses (10–15 mg/kg) are typically used for patients with cardiac risk factors or those receiving ibogaine for the first time. Higher doses (18–25 mg/kg) may be used for patients with severe opioid dependence or those who have received ibogaine before. The specific dose is determined by the treating physician or clinical director.

Test dose protocol: Before the full flood dose, a test dose of 1–3 mg/kg is administered. The patient is monitored for 30–60 minutes for cardiac adverse events, unusual sensitivity, or contraindicated reactions. If the test dose is well-tolerated, the remaining dose is administered. This protocol is a critical safety measure that should never be omitted.

HCl vs. TA dosing: Ibogaine HCl is the purified ibogaine alkaloid, standardized to a known concentration. Total alkaloid (TA) extract contains ibogaine plus other iboga alkaloids (ibogamine, ibogaline, tabernanthine) that contribute to the overall effect. TA is generally considered more potent per gram than HCl due to the synergistic effects of the other alkaloids. Dosing protocols must account for this difference.

Who determines the ibogaine dose?

In clinical settings, the dose is determined by the medical director or treating physician based on the patient's weight, medical history, indication, and the form of ibogaine being used. Integration coaches (Tier 1) do not determine dosing — this is a clinical facilitator (Tier 2) and physician responsibility.

What happens if the dose is too high?

An excessive ibogaine dose can cause prolonged QT interval, cardiac arrhythmias, seizures, and in severe cases, death. This is why cardiac monitoring and the test dose protocol are essential safety measures. If adverse cardiac effects are observed, the session must be managed as a medical emergency.

Can ibogaine be re-dosed during a session?

Re-dosing during a session is sometimes used to extend the experience or address incomplete withdrawal interruption. This must be done carefully, with full consideration of the cumulative cardiac effects. Re-dosing protocols are covered in the Tier 2 curriculum.

Is microdosing ibogaine effective?

Ibogaine microdosing (sub-perceptual doses of 1–5 mg/day) is being explored for ongoing neuroplasticity benefits and mood support. The evidence base is limited compared to flood dosing, but some practitioners use it as a follow-up to flood dose treatment. This is an emerging area not yet covered in standard certification curricula.